ReviewAntiviral research2012
The Syrian hamster model of hantavirus pulmonary syndrome.
Review in Antiviral research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 71 citations in OpenAlex.
- Hantavirus on the rise: clinical, virological, immunological, and public health perspectives.Current opinion in immunology · 2026Review
- Ribavirin post-exposure prophylaxis for Andes virus exposure: a viewpoint.EBioMedicine · 2026Review
- Circadian Behavioral and Bioluminescence Rhythms in theJournal of biological rhythms · 2026Article
- Review
- Amplification-free detection of zoonotic viruses using Cas13 and multiple CRISPR RNAs.The Journal of general virology · 2025Article
- High genomic stability of Andes virus following successive passageJournal of virology · 2025Article
- Differential tropisms of old and new world hantaviruses influence virulence and developing host-directed antiviral candidates.PLoS pathogens · 2025Article
- Sin Nombre Virus as Unlikely Reverse Zoonotic Threat.Emerging infectious diseases · 2025Article
- Puumala orthohantavirus: prevalence, biology, disease, animal models and recent advances in therapeutics development and structural biology.Frontiers in immunology · 2025Review
- Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters.Viruses · 2024Article
- Article
- Human-to-Human Transmission of Andes Virus Modeled in Syrian Hamsters.Emerging infectious diseases · 2023Article
- Animal models of mpox virus infection and disease.Infectious medicine · 2023Review
- Two point mutations in protocadherin-1 disrupt hantavirus recognition and afford protection against lethal infection.Nature communications · 2023Article
- Review
- Article
- Mean Girls: Social Stress Models for Female Rodents.Current topics in behavioral neurosciences · 2022Review
- Case report: Hemorrhagic fever with renal syndrome presenting as hemophagocytic lymphohistiocytosis.Frontiers in medicine · 2022Article
- Therapeutic Efficacy of Human Monoclonal Antibodies against Andes Virus Infection in Syrian Hamsters.Emerging infectious diseases · 2021Article
- Genetically-engineered hamster models: applications and perspective in dyslipidemia and atherosclerosis-related cardiovascular disease.Medical review (2021) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Hantavirus pulmonary syndrome (HPS) is a relatively rare, but frequently fatal disease associated with New World hantaviruses, most commonly Sin Nombre and Andes viruses in North and South America, respectively. It is characterized by fever and the sudden, rapid onset of severe respiratory distress and cardiogenic shock, which can be fatal in up to 50% of cases. Currently there are no approved antiviral therapies or vaccines for the treatment or prevention of HPS. A major obstacle in the development of effective medical countermeasures against highly pathogenic agents like the hantaviruses is recapitulating the human disease as closely as possible in an appropriate and reliable animal model. To date, the only animal model that resembles HPS in humans is the Syrian hamster model. Following infection with Andes virus, hamsters develop HPS-like disease which faithfully mimics the human condition with respect to incubation period and pathophysiology of disease. Perhaps most importantly, the sudden and rapid onset of severe respiratory distress observed in humans also occurs in hamsters. The last several years has seen an increase in studies utilizing the Andes virus hamster model which have provided unique insight into HPS pathogenesis as well as potential therapeutic and vaccine strategies to treat and prevent HPS. The purpose of this article is to review the current understanding of HPS disease progression in Syrian hamsters and discuss the suitability of utilizing this model to evaluate potential medical countermeasures against HPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.